The text starts here.

Access to Medicines

Lymphatic Filariasis

Status of DEC Provision Program for WHO

June 29, 2011

On 18th November, 2010, Eisai signed a statement of intent with the World Health Organization (WHO) to supply free of charge an essential medicine for the treatment of lymphatic filariasis. Eisai agreed to produce and supply up to 2.2 billion 100mg tablets of diethycarbamazine (“DEC”) in accordance with the high quality standards of WHO, over six years beginning in 2012. Production of the medicine is planned at Eisai's Vizag Plant in India.

Eisai's global team for this program, consisting of members mainly from Japan, India and Europe, is currently preparing for the distribution of Eisai DEC and is working in close communications with WHO.

Eisai is committed partner of WHO and works also with the Global Alliance to Eliminate Lymphatic Filariasis and the Global Network for Neglected Tropical Diseases to encourage the most effective elimination of lymphatic filariasis worldwide.

For the details of our DEC Provision Program, please see our News Release on 18th November, 2010, via the link below:

Related Links